(9ci)-4-(氨基甲基)-1-环己烯-1-羧酸 | 330838-52-3

• 物质功能分类: 分析化学 - 对照品
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (9ci)-4-(氨基甲基)-1-环己烯-1-羧酸
• 中文别名: 氨甲环酸相关物质C
• 英文名称: 1,2-Didehydro tranexamic acid
• 英文别名: 4-(aminomethyl)cyclohexene-1-carboxylic acid
• CAS: 330838-52-3
• 化学式: C₈H₁₃NO₂
• mdl: MFCD10001448
• 分子量: 155.19
• InChiKey: MZPZFPYJTSAQPX-UHFFFAOYSA-N

物化性质

• 熔点：
  >225oC (dec.)
• 沸点：
  306.6±25.0 °C(Predicted)
• 密度：
  1.151±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于甲醇（轻微）、水（轻微、超声处理）

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.625
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• WGK Germany：
  3

文献信息

• READY-TO-USE TRANEXAMIC ACID INTRAVENOUS SOLUTION
  申请人：RTU Pharma SA

  公开号：US20200078326A1

  公开（公告）日：2020-03-12

  Ready-to-use, stable aqueous intravenous tranexamic acid compositions are provided.

  提供了即用型、稳定的水溶性静脉用曲纳西酸组合物。
• Patch-type wound dressing comprising methylene blue mixture for treating skin wound
  申请人：D. R. NANO CO., LTD.

  公开号：US10695300B2

  公开（公告）日：2020-06-30

  There is provided a wound dressing prepared with a hydrocolloid gel, a polyurethane film, a PVA hydrogel, an alginate gel or the like, which has excellent stretchability and exudation absorbency of the wound surface for protection and prevention of infection on the wound surface in which continuity of a body tissue is destroyed by a physical impact or the like, can maintain a wet environment suitable for promoting healing of the wound surface, and has no pain or no worry to damage regenerated skin when the wound dressing is exchanged.

  本发明提供了一种使用水胶体凝胶、聚氨酯薄膜、PVA 水凝胶、藻酸盐凝胶等制备的伤口敷料，该敷料具有良好的伤口表面伸展性和渗出吸收性，可用于保护和预防因物理撞击等原因导致身体组织连续性遭到破坏的伤口表面的感染，可保持适合促进伤口表面愈合的湿润环境，并且在更换伤口敷料时不会产生疼痛，也不用担心会损伤再生皮肤。
• Ready-to-use tranexamic acid intravenous solution
  申请人：RTU Pharma SA

  公开号：US10980757B2

  公开（公告）日：2021-04-20

  Ready-to-use, stable aqueous intravenous tranexamic acid compositions are provided.

  提供了即用型、稳定的静脉注射氨甲环酸水溶液组合物。
• Methylene blue complex for treating skin disease and its use thereof
  申请人：D. R. NANO Co., Ltd.

  公开号：US11116842B2

  公开（公告）日：2021-09-14

  The present invention relates to complex particles using methylene blue for treating a skin disease caused by Propionibacterium acnes or Staphylococcus aureus and a composition for treatment including the complex particles. The complex particles in the present invention can be used as a photosensitizer for a photodynamic therapy and complex particles having a micelle form in which hydrophilic methylene blue and two hydrophobic organic acids are combined, and as a result, pore penetration is easy and an occlusion time can be significantly reduced to 30 minutes as compared with conventional phototherapy requiring an occlusion time of 1 hour to 3 hours. Further, in order to reduce side effects of a residual photosensitizer in phototherapy using an existing photosensitizer due to photoreaction and photobleaching of the methylene blue-organic acid complex, a light protection (light blocking or light shielding) time when contact of light needs to be avoided for 24 hours or more after treatment can be significantly reduced to 3 hours, and target treatment for Propionibacterium acnes, Staphylococcus aureus, or the like which is a cause of acne is possible.

  本发明涉及使用亚甲基蓝治疗由痤疮丙酸杆菌或金黄色葡萄球菌引起的皮肤病的复合物颗粒，以及包括该复合物颗粒的治疗组合物。本发明中的复合物微粒可用作光动力疗法的光敏剂，复合物微粒具有胶束形式，其中亲水性亚甲基蓝和两种疏水性有机酸结合在一起，因此，与传统光疗法需要 1 小时至 3 小时的闭塞时间相比，本发明中的复合物微粒易于毛孔渗透，闭塞时间可显著缩短至 30 分钟。此外，为了减少在使用现有光敏剂的光疗中因亚甲蓝-有机酸复合物的光反应和光漂白而产生的残留光敏剂的副作用，可将治疗后 24 小时或更长时间内需要避免接触光的光保护（光阻挡或光屏蔽）时间大幅缩短至 3 小时，并可对痤疮丙酸杆菌、金黄色葡萄球菌等导致痤疮的细菌进行针对性治疗。
• TRANEXAMIC ACID ORAL SOLUTION
  申请人：Hyloris Developments SA

  公开号：US20190224121A1

  公开（公告）日：2019-07-25

  Methods and compositions are provided for treating a patient having a bleeding disorder during or after a dental procedure to reduce bleeding or need for factor replacement therapy. Aqueous pharmaceutical compositions are provided comprising tranexamic acid, sodium carboxymethyl cellulose, Tween® 20, and menthol wherein the composition exhibits good long term stability, little to no discoloration over time, and reduced bitterness compared to a control solution of tranexamic acid and water.